IL13 and Alzheimer disease: Dupilumab, the first biologic agent targeting IL-4 receptor α, and tralokinumab, an IL-13 inhibitor, have demonstrated significant clinical efficacy, highlighting the critical roles of IL-4 and IL-13 in AD pathogenesis and treatment.